BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the ...

Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for ...

Commercial Channel revenue up 18% Integrity Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones ...

Q1 2025 Earnings Call Transcript May 8, 2025 Operator: Good day and welcome to the Delcath Systems’ First Quarter 2025 ...

Developing orphan drugs involves navigating intricate regulatory landscapes, financial risks, and limited clinical data. To ...

Q1 2025 Earnings Call Transcript May 8, 2025 John Menditto – VP of IR and Corporate Communications: David Mazzo – President and CEO: James Nisco – SVP of Finance and Treasury and Chief Accounting ...

In the first quarter of 2025, the Company completed a public offering of 5.1 million ordinary shares, including the full exercise of the underwriters' overallotment option, at a public offering price ...

Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment ...

Kenya Bonus Thirty, 000 Kes Iphone App, Subscribe, Aviator, Login, Review Content Quel Est The Montant Minimum Pour Un Retrait? To Login To Your Own 888 Mobile Edition Of … Leer más ...